Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -0.79% 62.50p 62.00p 63.00p 63.00p 62.50p 63.00p 57,065.00 10:22:57
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -1.4 1.8 35.7 48.85

Optibiotix H. Share Discussion Threads

Showing 19726 to 19746 of 19750 messages
Chat Pages: 790  789  788  787  786  785  784  783  782  781  780  779  Older
DateSubjectAuthorDiscuss
07/12/2016
15:12
colinzeal, i should think he has not got any firm news for that post. But sure to anything we are due some exciting news soon and the sooner it comes the better to stop this downtrend. As we all know a certain Tom w has been shouting from the rooftop for ages "news before Christmas", which has thus far been proved to be just idle words. His outfit may well still have a large holding after he top sliced a few at 100 so whether to believe him is another matter. But just who can you believe these days. Certainly no one on a BB is to be trusted.
neftanikoff
07/12/2016
14:04
Me too, buying HCM - 3 new global blockbuster cancer drugs to be launched in 2017 which will be material in terms of the Company valuation
nerdofsteel
07/12/2016
13:35
Couldn't help what , JJ ? Buying more shares here or downvoting Mazz because you have a crush on him?!
dogwalker
07/12/2016
09:53
They normally drop one in the morning one mid day and one towards close.
john henry
07/12/2016
09:51
Daily 10k sells as as regular as clockwork.
john henry
07/12/2016
09:25
Do not worry boys,girls, at least two new deals will be done soon.
diamond fibre
07/12/2016
08:18
Couldn't help it
judijudi
06/12/2016
20:23
F3rdinand, . . . . and then there's 6. Skinbiotix (which you sort of alluded to) and 7. a treatment for Parkinson's disease. SOH won't be too disappointed if all chickens don't come home to roost - but I will be; call it greed? 7 out of 7 and nothing less. So let's call a spade a spade - it's a 7-bagger, minimum. And 2017 is about right. I'm logging this for a repeat and "told you so" post sometime next year.
owenmo
06/12/2016
20:12
Indeed, Neft - TW have mentioned P&G at least twice over several months. I still believe they are involved. I would go as far as say I expect them to be the MN launching our first cardiovasculare product in spring 2017.
elrico
06/12/2016
20:12
To the person who downvoted every one of my comments today: do you have a crush on me or something?
mazzstar
06/12/2016
19:38
parob, DSM yes, but you know very well P & G has been cited for a very long time, am i right ?
neftanikoff
06/12/2016
18:50
One of the biggest opportunities is the ability to enhance the growth rate of specific microbes. The success of which has been shown recently. It swings open the door for deals right across the space From probiotic manufacturers to the animal feed markets. The dsm deal being a multi billion £ ingredient supplier gave opti early industry financial backing and its confidence. This targeted approach to improve the growth rate which can increase efficacy of a product is revolutionary. It gives the opportunity to not only use this tech to optimise Optis lpldl strain (which has already been shown) but many already on the market - starting with DSM. You can be pretty certain multiple deals with global players will materialise to optimise their products. Especially as the science is becoming clearer, giving more reasons for suppliers to use this tech to stay ahead of the curve. It Is jam tomorrow as this is still revolutionary science, the fact a deal such as this struck so early shows huge confidence in Optis tech.
riskybusiness1
06/12/2016
17:39
Basically what we're saying here is that OPTI will pretty much have a slice of every pie in the next few years... 1. Food will contain OPTI's calorie free sugars. 2. The nation will be losing weight through OPTI's slimbiome 'revolution'. 3. Cardiovascular disease will be slashed with our supplements and most probably pharma products prescribed by the NHS in years to come. 4. Beauty products will be adapted to bring health benefits/ work better. 5. Wounds and infections will be diminished through our technology. All massive markets...as others have rightly mentioned- all we need here is one MN deal and then the belief in the microbiome and thus in OPTI will increase tenfold. That's why i'm adding more while the wider market ignores our progress.
f3rdinand
06/12/2016
17:29
Thank you someuwin ;) This could be exciting!
mazzstar
06/12/2016
17:25
Good research mazz!
someuwin
06/12/2016
17:25
parob nitpick my words why don't you. You should know what I mean by support and confidence behind the product and to spell it out for you since it's not clear enough I meant A CONFIRMED DEAL!
mazzstar
06/12/2016
17:23
I'm thinking shampoo I'm thinking Johnson & Johnson.
mazzstar
06/12/2016
17:14
I googled Cath O'Neill and came across a job that was posted 2 weeks ago. Interesting that it mentions the scalp, I wonder what Opti are up to...? 'Research Technician in Musculoskeletal and Dermatological Sciences. You will be engaged full time in research to investigate the microbiota of the scalp in healthy individuals and those with dandruff. This work will involve studying barrier markers in ex vivo skin innoculated with scalp microbiota, as a model system. You will be part of a team which investigates skin barrier function in health and disease and how the microbiota interact with the epidermal barrier. You must have at least a B.Sc in a biological science, or equivalent experience. Previous experience in the fields of skin biology or microbiology will be an advantage...Enquiries about the vacancy, shortlisting and interviews: Dr Cath O'Neill' hxxps://www.totaljobs.com/job/research-technician/university-of-manchester-job67251745
mazzstar
06/12/2016
17:08
Mazz, you've just said:"It's not even revenues we should be concerned about, it is industry confidence and support behind these products.""OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic(R) technology platform. Royal DSM is a global science based company active in health, nutrition and materials with approximately 25,000 employees and annual net sales in the region of EUR10 billion. Its Nutritional Products business is one of the world's leading suppliers of vitamins, carotenoids, nutritional lipids and other ingredients in the food, pharmaceutical and personal care industries."If that's not major industry backing, I don't know what is!
parob
06/12/2016
17:05
true parob but support with £££; not just on paper
mazzstar
06/12/2016
17:00
Yeah it's not like Royal DSM are a global multi-billion turnover over company....
parob
Chat Pages: 790  789  788  787  786  785  784  783  782  781  780  779  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161208 00:10:49